Dual egg retrieaval for poor prognosis women

Double trigger and ovum retrieval vs. conventional antagonist ovarian stimulation protocol in poor prognosis women undergoing IVF/ICSI: A pilot study - DUOPICK

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2019-000971-17-BE

Enrollment

Registered

2019-05-14

Start date

2019-07-17

Completion date

Unknown

Last updated

2024-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility

Interventions

Trade Name: Elonva Product Name: Elonva Pharmaceutical Form: Solution for injection INN or Proposed INN: CORIFOLLITROPIN ALFA CAS Number: 195962-23-3 Current Sponsor code: 58335-Elonva Concentration u

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Age 25-40 years - BMI = 35 and = 19 -Antimüllerian hormone (AMH) level of =1.5 ng/mL or antral follicular count of =6 follicles or =5 oocytes retrieved in a previous cycle following standard conventional ovarian stimulation. - =9 follicles >11 mm on the day of first trigger Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 46 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: history of more than three consecutive previous unsuccessful IVF/ICSI cycles, BMI >35 or 3 months before start of the treatment, testicular sperm extraction; history of untreated autoimmune, endocrine or metabolic disorders, ovarian cystectomy or oophorectomy.

Design outcomes

Primary

Measure	Time frame
Main Objective: The purpose of this pilot study is to compare the efficacy of double trigger with GnRH agonist vs. conventional antagonist ovarian stimulation protocol in poor prognosis patients undergoing IVF/ICSI. ;Secondary Objective: Not applicable;Primary end point(s): Number of metaphase II (MIIs) oocytes ;Timepoint(s) of evaluation of this end point: 1 month	—

Secondary

Measure	Time frame
Secondary end point(s): Secondary outcome measures will include: number of preovulatory follicles, number of cumulus oocyte complexes (COCs) retrieved, number of oocytes fertilized, total number of available embryos, duration of stimulation, total dose of gonadotropins administered, clinical pregnancy and live birth rates and cumulative live birth rates (defined as the first live birth following the transfer of fresh and subsequent frozen-thawed embryos). In both groups, measurement (mean diameter) of all aspirated follicles will be performed on the day of the first and second OR (for group B). ;Timepoint(s) of evaluation of this end point: 2 years	—

Measure

Time frame

Secondary end point(s): Secondary outcome measures will include: number of preovulatory follicles, number of cumulus oocyte complexes (COCs) retrieved, number of oocytes fertilized, total number of available embryos, duration of stimulation, total dose of gonadotropins administered, clinical pregnancy and live birth rates and cumulative live birth rates (defined as the first live birth following the transfer of fresh and subsequent frozen-thawed embryos). In both groups, measurement (mean diameter) of all aspirated follicles will be performed on the day of the first and second OR (for group B). ;Timepoint(s) of evaluation of this end point: 2 years

—

Countries

Belgium

Contacts

Public ContactPanagiotis Drakopoulos

UZ Brussel

00320468180349

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026